Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Comment by McLachertyon Dec 13, 2010 8:59am
175 Views
Post# 17837140

RE: Most Undervalued Juniors Ready to Leap to the

RE: Most Undervalued Juniors Ready to Leap to thehbm announcement and I believe they are talking about our zinc JMO HudBay's domestic zinc concentrate production in 2011 is expected to supply approximately 70% of the plant's capacity. An additional 65,000 tonnes of zinc concentrate is expected to be purchased from third parties, of which commitments to purchase 50,000 tonnes are already in place. Operating costs at the zinc plant are expected to be similar to 2010 levels, as higher cost allocations in 2011 following the copper smelter closure offset costs incurred in the second quarter of 2010 during the biennial maintenance shutdown. Costs in any particular quarter can also vary from the annual guidance above based on a variety of factors including the scheduling of maintenance events and seasonal heating requirements. ----------Original Message Posted 12/13/2010---------- Lost included in HBMs 2011 plans plus more exploration, looking good for us. JMO ----------Original Message Posted 12/12/2010 12:34:05 AM---------- Good post, Thanks !
<< Previous
Bullboard Posts
Next >>